|
|
 |
OSCO NEWS |
|
 |
Sep 28, '07 |
U. S. Food and Drug Administration (FDA) approved docetaxel ( TaxotereŽ Injection Concentrate - On September 28, 2007, the U. S. Food and Drug Administration (FDA) approved docetaxel ( TaxotereŽ Injection Concentrate, Sanofi-Aventis) for use in combination with cisplatin and fluorouracil (5-FU) for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).  read more |
|
Sep 25, '07 |
recent changes made to the AvastinŽ Injection prescription information - This communication informs you of recent changes made to the AvastinŽ Injection prescription information. On March, 2007 the FDA was informed of the occurrence of two confirmed and one suspected cases of tracheoesophageal fistula in an investigator-sponsored trial using bevacizumab concurrently with chemoradiation in the treatment of limited-stage small cell lung cancer. Three cases were fatal. The trial was closed and a Dear Healthcare Provider letter was issued. read more |
|
Sep 13, '07 |
FDA approves EVISTA - on September 13, 2007, the US FDA approved raloxifene hydrochloride tablets (EVISTA, Eli Lilly and Company) for reduction in the risk of invasive breast cancer in postmenopausal women.... read more |
|
Sep 06, '07 |
FDA approves Totect - On September 6, 2007 the US FDA approved dexrazoxane hydrochloride for injection (Totect), equivalent to 500 mg dexrazoxane, for the treatment of extravasation resulting from intravenous anthracycline chemotherapy. read more |
|
Aug 02, '07 |
TrailBlazer will be the A/B MAC for Jurisdiction 4 - read more |
|
Aug 02, '07 |
Continued...TrailBlazer will be the A/B MAC for Jurisdiction 4 - read more |
|
Jun 27, '07 |
Reach out to your Representatives on the ESA National Coverage Determination - read more |
|
Jun 27, '07 |
Comment letter that COA submitted to CMS regarding the proposed NCD - Attached is the comment letter that COA submitted to CMS regarding the proposed NCD. This may be helpful background information in discussing this issue with your Representatives.
read more |
|
Jun 27, '07 |
Testimony of Leslie B. Norwalk, Esp. on "Payment, Safety and quality Issues in Treatment of Patennts with EDRD" - Testimony of Leslie B. Norwalk, Esp., Acting Administrator,Centers for Medicare & Medicaid Services befroe the U.S. House of Representatives Ways and Means Subcommittee on Health on "Payment, Safety and quality Issues in Treatment of Patennts with EDRD" read more |
|
May 30, '07 |
FDA grants approval for temsirolumus (TORISEL, Wyeth, Inc.) - On May 30, 2007, the US Food and Drug Administration granted approval for temsirolumus (TORISEL, Wyeth, Inc.)for the treatment of advanced renal cell carcinoma (RCC). read more |
|
| |
|
